Dianthus Therapeutics, Inc. /DE/ (DNTH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 800K 1.6M 2.4M Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q3 '22: 1.2M Q4 '22: 1.2M Q3 '23: 924K Q4 '23: 457K Q1 '24: 874K Q2 '24: 1.9M Q3 '24: 2.2M Q4 '24: 1.3M Q1 '25: 1.2M Q2 '25: 193K Q3 '25: 396K Q4 '25: 284K Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q4 '23 Q4 '24 Q4 '25

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '17: -4.8M Q2 '17: -15.7M Q3 '17: -7M Q4 '17: -8.2M Q1 '18: -11.3M Q2 '18: -14M Q3 '18: -16.7M Q4 '18: -17.9M Q1 '19: -16.4M Q2 '19: -19.3M Q3 '19: -22.6M Q4 '19: -24.6M Q1 '20: -21.2M Q2 '20: -20M Q3 '20: -18.4M Q4 '20: -19.1M Q1 '21: -18.7M Q2 '21: -17.6M Q3 '21: -18.2M Q4 '21: -20.1M Q1 '22: -23.8M Q2 '22: -18.1M Q3 '22: -8.3M Q4 '22: 20.5M Q1 '23: -7.7M Q2 '23: -11.8M Q3 '23: -15.8M Q4 '23: -13M Q1 '24: -17.8M Q2 '24: -22.2M Q3 '24: -29.9M Q4 '24: -31.9M Q1 '25: -33.2M Q2 '25: -34.9M Q3 '25: -40.3M Q4 '25: -69.5M Q1 '26: -46.5M Q2 '26: -61.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '17: -4.8M Q2 '17: -15.7M Q3 '17: -6.9M Q4 '17: -8M Q1 '18: -11.2M Q2 '18: -13.7M Q3 '18: -16M Q4 '18: -16.7M Q1 '19: -14.8M Q2 '19: -17.7M Q3 '19: -21M Q4 '19: -23.2M Q1 '20: -20M Q2 '20: -19.1M Q3 '20: -17.7M Q4 '20: -18.2M Q1 '21: -17.5M Q2 '21: -16.9M Q3 '21: -17.4M Q4 '21: -19.3M Q1 '22: -4.9M Q2 '22: -5.7M Q3 '22: -7.8M Q4 '22: -10.1M Q1 '23: -7.1M Q2 '23: -11.1M Q3 '23: -14.8M Q4 '23: -10.6M Q1 '24: -13.7M Q2 '24: -17.6M Q3 '24: -25.2M Q4 '24: -28.4M Q1 '25: -29.5M Q2 '25: -31.6M Q3 '25: -36.8M Q4 '25: -64.4M Q1 '26: -40.8M Q2 '26: -50.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '17: -5.4M Q4 '17: -8.2M Q1 '18: -9.6M Q2 '18: -9.1M Q3 '18: -10.5M Q4 '18: -12.6M Q1 '19: -14.9M Q2 '19: -15M Q3 '19: -11.5M Q4 '19: -15.6M Q1 '20: -16.7M Q2 '20: -19.2M Q3 '20: -14.4M Q4 '20: -13.7M Q1 '21: -16.8M Q2 '21: -13M Q3 '21: -14.1M Q4 '21: -15.7M Q1 '22: -19.7M Q2 '22: -16.9M Q3 '22: 16.4M Q4 '22: -8.9M Q1 '23: -10.3M Q2 '23: -4.7M Q3 '23: -10M Q4 '23: -11.9M Q1 '24: -14.9M Q2 '24: -14.5M Q3 '24: -21.3M Q4 '24: -27.4M Q1 '25: -27.6M Q2 '25: -23.9M Q3 '25: -30.6M Q4 '25: -47M Q1 '26: -28.9M Q2 '26: -49M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '17: -5.8M Q4 '17: -8.5M Q1 '18: -9.8M Q2 '18: -9.8M Q3 '18: -13M Q4 '18: -17M Q1 '19: -16.2M Q2 '19: -16.2M Q3 '19: -12M Q4 '19: -15.8M Q1 '20: -16.8M Q2 '20: -19.2M Q3 '20: -14.4M Q4 '20: -13.9M Q1 '21: -16.8M Q2 '21: -13.1M Q3 '21: -15.2M Q4 '21: -15.7M Q1 '22: -19.8M Q2 '22: -17M Q3 '22: 16.2M Q4 '22: -8.9M Q1 '23: -10.5M Q2 '23: -4.7M Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '21: 48.6M Q2 '21: 53.7M Q3 '21: 58.6M Q1 '22: 58.8M Q2 '22: 58.8M Q3 '22: 874.3K Q1 '23: 874.7K Q2 '23: 874.9K Q3 '23: 3.9M Q1 '24: 25.7M Q2 '24: 34.2M Q3 '24: 34.2M Q1 '25: 35.8M Q2 '25: 35.8M Q3 '25: 37.8M Q1 '26: 48M Q2 '26: 56M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '17: -19.52 Q1 '18: -20.46 Q2 '18: -14.69 Q3 '18: -11.74 Q4 '18: -8.65 Q1 '19: -4.56 Q2 '19: -1.91 Q3 '19: -1.96 Q4 '19: -2.05 Q1 '20: -2.12 Q2 '20: -2.12 Q3 '20: -1.95 Q4 '20: -1.73 Q1 '21: -1.58 Q2 '21: -1.42 Q3 '21: -1.35 Q4 '21: -1.30 Q1 '23: -28.86 Q2 '23: -41.30 Q3 '23: -36.18 Q4 '23: -8.45 Q1 '24: -0.89 Q2 '24: 11.33 Q3 '24: 14.37 Q4 '24: -2.61 Q1 '25: -2.89 Q2 '25: -3.26 Q3 '25: -3.49 Q4 '25: -4.19 Q1 '26: -4.22 Q2 '26: -4.24 Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.